ArticleCureus2026
Successful Treatment of Acanthamoeba Keratitis Using 0.08% Polyhexamethylene Biguanide Monotherapy: A Report of a Case in Latin America.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acanthamoeba keratitis (AK) is a rare but potentially sight-threatening corneal infection, most commonly associated with contact lens use, and frequently misdiagnosed due to its nonspecific early clinical presentation. Standard treatment regimens are prolonged and often limited by ocular surface toxicity and poor patient adherence. We report the case of a 19-year-old contact lens wearer who presented with a one-month history of ocular pain, redness, photophobia, and decreased vision in the right eye, initially treated as viral keratitis without improvement. Slit-lamp examination revealed stromal infiltrates with perineural involvement, and in vivo confocal microscopy confirmed the presence of superficial Acanthamoeba cysts without fungal elements. The patient was treated using a standardized protocol with topical polyhexamethylene biguanide (PHMB) 0.08% monotherapy, resulting in rapid clinical improvement, progressive reduction of corneal infiltrates, and complete resolution of active infection. Best-corrected visual acuity improved from 20/400 to 20/25, with no evidence of recurrence during seven months of follow-up. This case supports the potential role of PHMB 0.08% monotherapy as an effective and well-tolerated therapeutic option for AK.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.